← Back to Screener
Chemomab Therapeutics Ltd. American Depositary Share (CMMB)
Price$1.86
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-33.63%
Price vs S&P 500 (4W)19.39%
VGM Score43.65
Market Capitalization$14.40M
All Metrics
Book Value / Share (Quarterly)$0.02
P/TBV (Annual)0.18x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.02
Price vs S&P 500 (YTD)10.28%
EPS (TTM)$-0.03
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-0.03
EPS (Annual)$-0.02
ROI (Annual)-72.93%
Cash / Share (Quarterly)$0.01
ROA (Last FY)-65.12%
EBITD / Share (TTM)$-0.01
ROE (5Y Avg)-83.02%
Cash Flow / Share (Annual)$-0.02
P/B Ratio1.35x
P/B Ratio (Quarterly)1.06x
Net Income / Employee (Annual)$-749,600
Net Interest Coverage (TTM)-112.45x
ROA (TTM)-60.63%
EPS Incl Extra (Annual)$-0.02
Current Ratio (Annual)9.08x
Quick Ratio (Quarterly)7.23x
3-Month Avg Trading Volume0.06M
52-Week Price Return-63.30%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$28.37
52-Week High$5.56
EPS Excl Extra (Annual)$-0.02
CapEx CAGR (5Y)-40.43%
26-Week Price Return-17.70%
Quick Ratio (Annual)7.01x
13-Week Price Return29.03%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.31x
Enterprise Value$8.49M
Book Value / Share Growth (5Y)-74.18%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.02
3-Month Return Std Dev88.36%
Net Income / Employee (TTM)$-620,400
ROE (Last FY)-72.93%
Net Interest Coverage (Annual)-24.86x
EPS Basic Excl Extra (Annual)$-0.02
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.03
ROI (TTM)-67.74%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$49.83
Price vs S&P 500 (52W)-91.51%
Year-to-Date Return21.21%
5-Day Price Return-0.99%
EPS Normalized (Annual)$-0.02
ROA (5Y Avg)-68.05%
Month-to-Date Return36.05%
Cash Flow / Share (TTM)$-47.12
EBITD / Share (Annual)$-0.02
ROI (5Y Avg)-83.02%
EPS Basic Excl Extra (TTM)$-0.03
P/TBV (Quarterly)0.30x
P/B Ratio (Annual)0.82x
Book Value / Share (Annual)$0.02
Price vs S&P 500 (13W)19.29%
Beta0.63x
Revenue / Share (TTM)$0.00
ROE (TTM)-67.74%
52-Week Low$1.35
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.24est. -0.16
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CMMBChemomab Therapeutics Ltd. American Depositary Share | — | — | C | $1.86 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Chemomab Therapeutics is a clinical-stage biotech company developing CM-101, a monoclonal antibody targeting CCL24 for fibrosis-related diseases with significant unmet medical needs. The company's lead candidate employs a novel mechanism to address liver, skin, and lung fibrosis, with three Phase 2 trials currently underway for rare fibrotic conditions.